Yahoo Web Search

Search results

1. • 

     The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record

     Investor's Business Daily· 6 days ago

     Avidity Biosciences unveiled "impressive" results from a study of its treatment for a rare form of ...

2. • 

     Pfizer 'can't rule out' layoffs in North Carolina after gene therapy flub - Triangle Business...

     The Business Journals· 8 hours ago

     Layoffs could by on the way at Pfizer's massive facility in Sanford after the company's gene therapy...

3. • 

     FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy

     Medical Xpress· 2 days ago

     The U.S. Food and Drug Administration has approved the first generic version of Emflaza...

4. • 

     Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

     BioPharma Dive via Yahoo Finance· 7 days ago

     Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity...

5. • 

     Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival

     Barrons.com· 5 days ago

     SECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...

6. • Pfizer's gene-therapy trial failure boosts Sarepta's stock

     Morningstar· 6 days ago

     Shares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...

7. • 

     $10,000 for 10 years: Chesterfield-based organization helping those with neuromuscular disorders

     WRIC 8 News Richmond· 6 days ago

     For ten years, the Colorado Fund for Muscular Dystrophy (CMFD) has been working to improve the lives...

8. • Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...

     Morningstar· 6 days ago

     The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory...

9. • 

     Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal

     The Business Journals· 6 days ago

     Sarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...

10. • 

      Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy

      FierceBiotech· 7 days ago

      Avidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to...